Header Logo

Connection

Co-Authors

Back to Details
This is a "connection" page, showing publications co-authored by CULLEN TANIGUCHI and EUGENE JON KOAY.
CULLEN TANIGUCHI
Connection Strength
5.684
EUGENE JON KOAY
  1. Escalated-dose radiotherapy for unresected locally advanced pancreatic cancer: Patterns of care and survival in the United States. Cancer Med. 2024 Jun; 13(12):e7434.
    View in: PubMed
    Score: 0.240
  2. Phase I trial of single-photon emission computed tomography-guided liver-directed radiotherapy for patients with low functional liver volume. JNCI Cancer Spectr. 2024 Apr 30; 8(3).
    View in: PubMed
    Score: 0.239
  3. Stereotactic body radiotherapy with or without selective dismutase mimetic in pancreatic adenocarcinoma: an adaptive, randomised, double-blind, placebo-controlled, phase 1b/2 trial. Lancet Oncol. 2023 12; 24(12):1387-1398.
    View in: PubMed
    Score: 0.232
  4. Definitive Liver Radiotherapy for Intrahepatic Cholangiocarcinoma with Extrahepatic Metastases. Liver Cancer. 2023 Aug; 12(3):198-208.
    View in: PubMed
    Score: 0.221
  5. Nab-Paclitaxel, Capecitabine, and Radiation Therapy After Induction Chemotherapy in Treating Patients With Locally Advanced and Borderline Resectable Pancreatic Cancer: Phase 1 Trial and Imaging-based Biomarker Validation. Int J Radiat Oncol Biol Phys. 2022 11 01; 114(3):444-453.
    View in: PubMed
    Score: 0.211
  6. Mass Transport Model of Radiation Response: Calibration and Application to Chemoradiation for Pancreatic Cancer. Int J Radiat Oncol Biol Phys. 2022 09 01; 114(1):163-172.
    View in: PubMed
    Score: 0.209
  7. Ablative liver radiotherapy for unresected intrahepatic cholangiocarcinoma: Patterns of care and survival in the United States. Cancer. 2022 07 01; 128(13):2529-2539.
    View in: PubMed
    Score: 0.207
  8. NBTXR3, a first-in-class radioenhancer for pancreatic ductal adenocarcinoma: Report of first patient experience. Clin Transl Radiat Oncol. 2022 Mar; 33:66-69.
    View in: PubMed
    Score: 0.203
  9. Benchmarking Outcomes after Ablative Radiotherapy for Molecularly Characterized Intrahepatic Cholangiocarcinoma. J Pers Med. 2021 Dec 01; 11(12).
    View in: PubMed
    Score: 0.202
  10. Stereotactic Versus Conventional Radiation Therapy for Patients With Pancreatic Cancer in the Modern Era. Adv Radiat Oncol. 2021 Nov-Dec; 6(6):100763.
    View in: PubMed
    Score: 0.197
  11. Radiation-Associated Lymphopenia and Outcomes of Patients with Unresectable Hepatocellular Carcinoma Treated with Radiotherapy. J Hepatocell Carcinoma. 2021; 8:57-69.
    View in: PubMed
    Score: 0.192
  12. Impact of Fiducial Marker Placement Before Stereotactic Body Radiation Therapy on Clinical Outcomes in Patients With Pancreatic Cancer. Adv Radiat Oncol. 2021 Mar-Apr; 6(2):100621.
    View in: PubMed
    Score: 0.188
  13. Patient-Reported GI Outcomes in Patients With Anal Cancer Receiving Modern Chemoradiation. JCO Oncol Pract. 2020 12; 16(12):e1524-e1531.
    View in: PubMed
    Score: 0.183
  14. Dose-Escalated Radiation Therapy for Pancreatic Cancer: A Simultaneous Integrated Boost Approach. Pract Radiat Oncol. 2020 Nov - Dec; 10(6):e495-e507.
    View in: PubMed
    Score: 0.178
  15. Mitochondrial fusion exploits a therapeutic vulnerability of pancreatic cancer. JCI Insight. 2019 07 23; 5.
    View in: PubMed
    Score: 0.171
  16. Selective EGLN Inhibition Enables Ablative Radiotherapy and Improves Survival in Unresectable Pancreatic Cancer. Cancer Res. 2019 05 01; 79(9):2327-2338.
    View in: PubMed
    Score: 0.169
  17. Dose escalation for locally advanced pancreatic cancer: How high can we go? Adv Radiat Oncol. 2018 Oct-Dec; 3(4):693-700.
    View in: PubMed
    Score: 0.163
  18. Dose escalation of radiotherapy in unresectable extrahepatic cholangiocarcinoma. Cancer Med. 2018 10; 7(10):4880-4892.
    View in: PubMed
    Score: 0.161
  19. A Visually Apparent and Quantifiable CT Imaging Feature Identifies Biophysical Subtypes of Pancreatic Ductal Adenocarcinoma. Clin Cancer Res. 2018 12 01; 24(23):5883-5894.
    View in: PubMed
    Score: 0.160
  20. Imaging-based biomarkers: Changes in the tumor interface of pancreatic ductal adenocarcinoma on computed tomography scans indicate response to cytotoxic therapy. Cancer. 2018 04 15; 124(8):1701-1709.
    View in: PubMed
    Score: 0.155
  21. Definitive radiation therapy for hepatocellular carcinoma with portal vein tumor thrombus. Clin Transl Radiat Oncol. 2017 Jun; 4:39-45.
    View in: PubMed
    Score: 0.148
  22. Dose escalation with an IMRT technique in 15 to 28 fractions is better tolerated than standard doses of 3DCRT for LAPC. Adv Radiat Oncol. 2017 Jul-Sep; 2(3):403-415.
    View in: PubMed
    Score: 0.146
  23. Addition of Metastasis-Directed Therapy to Systemic Therapy for Oligometastatic Pancreatic Ductal Adenocarcinoma (EXTEND): A Multicenter, Randomized Phase II Trial. J Clin Oncol. 2024 Nov 10; 42(32):3795-3805.
    View in: PubMed
    Score: 0.061
  24. Long-Term Patient-Reported Dyspareunia After Definitive Chemoradiation for Anal Cancer: Using the Anterior Vaginal Wall as an Organ-at-Risk to Define an Actionable Dosimetric Goal. Adv Radiat Oncol. 2024 May; 9(5):101449.
    View in: PubMed
    Score: 0.059
  25. Endoscopic Ultrasound-Guided Fiducial Placement for Stereotactic Body Radiation Therapy in Patients with Pancreatic Cancer. Cancers (Basel). 2023 Nov 10; 15(22).
    View in: PubMed
    Score: 0.058
  26. Brain Metastases from Biliary Tract Cancer: Case Series and Clinicogenomic Analysis. Oncologist. 2023 04 06; 28(4):327-332.
    View in: PubMed
    Score: 0.055
  27. Differential Spatial Gene and Protein Expression Associated with Recurrence Following Chemoradiation for Localized Anal Squamous Cell Cancer. Cancers (Basel). 2023 Mar 10; 15(6).
    View in: PubMed
    Score: 0.055
  28. Patient-reported Bowel Function and Bowel-related Quality of Life After Pelvic Radiation for Rectal Adenocarcinoma: The Impact of Radiation Fractionation and Surgical Resection. Clin Colorectal Cancer. 2023 06; 22(2):211-221.
    View in: PubMed
    Score: 0.055
  29. Patient-Reported Sexual Function in Long-Term Survivors of Anal Cancer Treated With Definitive Intensity Modulated Radiation Therapy and Concurrent Chemotherapy. Pract Radiat Oncol. 2022 Sep-Oct; 12(5):e397-e405.
    View in: PubMed
    Score: 0.052
  30. Patient-Reported Bowel and Urinary Function in Long-Term Survivors of Squamous Cell Carcinoma of the Anus Treated With Definitive Intensity Modulated Radiation Therapy And Concurrent Chemotherapy. Int J Radiat Oncol Biol Phys. 2022 09 01; 114(1):78-88.
    View in: PubMed
    Score: 0.052
  31. Patient-Reported Outcomes After Chemoradiation in Patients With Anal Cancer: A Qualitative Analysis. Adv Radiat Oncol. 2022 Jul-Aug; 7(4):100986.
    View in: PubMed
    Score: 0.052
  32. Contemporary use and outcomes of radiation and chemotherapy for unresectable pancreatic cancer. Clin Transl Radiat Oncol. 2022 Jul; 35:9-16.
    View in: PubMed
    Score: 0.052
  33. Outcomes and Toxicities of Modern Combined Modality Therapy with Atezolizumab Plus Bevacizumab and Radiation Therapy for Hepatocellular Carcinoma. Cancers (Basel). 2022 Apr 09; 14(8).
    View in: PubMed
    Score: 0.052
  34. Definitive Intensity-Modulated Chemoradiation for Anal Squamous Cell Carcinoma: Outcomes and Toxicity of 428 Patients Treated at a Single Institution. Oncologist. 2022 02 03; 27(1):40-47.
    View in: PubMed
    Score: 0.051
  35. Expansion of Candidate HPV-Specific T Cells in the Tumor Microenvironment during Chemoradiotherapy Is Prognostic in HPV16+ Cancers. Cancer Immunol Res. 2022 02; 10(2):259-271.
    View in: PubMed
    Score: 0.051
  36. Intraoperative Radiation After Pelvic Short Course Radiation-Based Total Neoadjuvant Therapy for Patients With Rectal Adenocarcinoma at High Risk for Local Recurrence. Clin Colorectal Cancer. 2022 09; 21(3):204-211.
    View in: PubMed
    Score: 0.051
  37. Benchmarking Outcomes for Definitive Treatment of Young-Onset, Locally Advanced Rectal Cancer. Clin Colorectal Cancer. 2022 03; 21(1):e28-e37.
    View in: PubMed
    Score: 0.050
  38. Prognostic impact of lymphopenia and neutrophil-lymphocyte ratio for patients with anal squamous cell carcinoma. J Gastrointest Oncol. 2021 Oct; 12(5):2412-2422.
    View in: PubMed
    Score: 0.050
  39. Dosimetric Uncertainties Resulting From Interfractional Anatomic Variations for Patients Receiving Pancreas Stereotactic Body Radiation Therapy and Cone Beam Computed Tomography Image Guidance. Int J Radiat Oncol Biol Phys. 2021 12 01; 111(5):1298-1309.
    View in: PubMed
    Score: 0.049
  40. CEA as a blood-based biomarker in anal cancer. Oncotarget. 2021 May 25; 12(11):1037-1045.
    View in: PubMed
    Score: 0.049
  41. A Machine Learning Model Approach to Risk-Stratify Patients With Gastrointestinal Cancer for Hospitalization and Mortality Outcomes. Int J Radiat Oncol Biol Phys. 2021 09 01; 111(1):135-142.
    View in: PubMed
    Score: 0.048
  42. Implementation of a stereotactic body radiotherapy program for unresectable pancreatic cancer in an integrated community academic radiation oncology satellite network. Clin Transl Radiat Oncol. 2021 Mar; 27:147-151.
    View in: PubMed
    Score: 0.048
  43. Pathologic Response and Postoperative Complications After Short-course Radiation Therapy and Chemotherapy for Patients With Rectal Adenocarcinoma. Clin Colorectal Cancer. 2020 06; 19(2):116-122.
    View in: PubMed
    Score: 0.045
  44. Evaluation of the Visibility and Artifacts of 11 Common Fiducial Markers for Image Guided Stereotactic Body Radiation Therapy in the Abdomen. Pract Radiat Oncol. 2020 Nov - Dec; 10(6):434-442.
    View in: PubMed
    Score: 0.044
  45. IMRT Reduces Acute Toxicity in Patients Treated With Preoperative Chemoradiation for Gastric Cancer. Adv Radiat Oncol. 2020 May-Jun; 5(3):369-376.
    View in: PubMed
    Score: 0.044
  46. Assessment of setup uncertainty in hypofractionated liver radiation therapy with a breath-hold technique using automatic image registration-based image guidance. Radiat Oncol. 2019 Aug 30; 14(1):154.
    View in: PubMed
    Score: 0.043
  47. Definitive hyperfractionated, accelerated proton reirradiation for patients with pelvic malignancies. Clin Transl Radiat Oncol. 2019 Nov; 19:59-65.
    View in: PubMed
    Score: 0.043
  48. Novel EUS-guided brachytherapy treatment of pancreatic cancer with phosphorus-32 microparticles: first United States experience. VideoGIE. 2019 May; 4(5):223-225.
    View in: PubMed
    Score: 0.042
  49. Proton beam therapy outcomes for localized unresectable hepatocellular carcinoma. Radiother Oncol. 2019 04; 133:54-61.
    View in: PubMed
    Score: 0.041
  50. Circulating Nucleic Acids Are Associated With Outcomes of Patients With Pancreatic Cancer. Gastroenterology. 2019 01; 156(1):108-118.e4.
    View in: PubMed
    Score: 0.040
  51. Hyperfractionated abdominal reirradiation for gastrointestinal malignancies. Radiat Oncol. 2018 Aug 07; 13(1):143.
    View in: PubMed
    Score: 0.040
  52. Treatment of primary rectal adenocarcinoma after prior pelvic radiation: The role of hyperfractionated accelerated reirradiation. Adv Radiat Oncol. 2018 Oct-Dec; 3(4):595-600.
    View in: PubMed
    Score: 0.040
  53. Short course radiation as a component of definitive multidisciplinary treatment for select patients with metastatic rectal adenocarcinoma. J Gastrointest Oncol. 2017 Dec; 8(6):990-997.
    View in: PubMed
    Score: 0.038
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.